Pharmacology Biochemical Pharmacology
Oroxylin A calms pneumonia by curbing macrophage ferroptosis via HSP90α
- In a mouse pneumonia model, the natural compound Oroxylin A eased weight loss, lung tissue damage and inflammatory signaling; single-cell RNA sequencing pointed to macrophages as the main responding cells.
- In LPS-stimulated macrophages it dampened cytokine output and raised the ferroptosis-protective factors GPX4 and SLC7A11, an effect blunted by the ferroptosis inducer erastin.
- Target-profiling, molecular dynamics and thermal-shift assays nominated HSP90α as a likely binding partner, linking it to the ferroptosis-driven inflammation (the abstract is truncated beyond this point).
A flavonoid with a plausible HSP90α hit is exactly where I'd demand genetic proof before believing the mechanism. HSP90 is a notoriously promiscuous chaperone, so CETSA shift plus docking doesn't show the phenotype runs through it. I'd want HSP90α knockdown abolishing the benefit, plus a ferroptosis inhibitor rescue in vivo, and lung exposure at the dose used.
Paper: Biochemical Pharmacology ↗ Oroxylin A attenuates pneumonia via HSP90α-dependent suppression of macrophage ferroptosis-mediated inflammation